Conditions: Breast Cancer Prostate Cancer Bone Neoplasms
Keywords: breast cancer prostate cancer metastatic bone disease Subjects with breast cancer or prostate cancer with metastatic bone disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 139
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.

Detailed description:

Arms:
arm 1: AZD0530 (saracatinib) 175 mg once daily arm 2: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period

Interventions: intervention 1: AZD0530 intervention 2: Zoledronic Acid
Intervention descriptions: intervention 1: Daily oral dose intervention 2: None

Protocol document: